title: Hormonal regulation of 18S RNA, leptin mRNA, and leptin release in adipocytes from hypothyroid rats.
abstract: The present studies were designed to examine the regulation of leptin release in primary cultures of adipocytes from fed hypothyroid rats incubated with hormones for 24 hours. Leptin release was increased in the presence of dexamethasone, while the decrease in leptin mRNA content over a 24-hour incubation was reduced by dexamethasone. Dexamethasone did not affect the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA or 18S RNA content of adipocytes. Insulin increased leptin release by adipocytes in both the absence and presence of dexamethasone. Although insulin also prevented the loss of leptin mRNA, this effect was less than that observed for GAPDH mRNA or 18S RNA content. In isolated adipocytes, the loss of almost half the 18S RNA content over a 24-hour incubation was prevented in the presence of insulin but not oxytocin or epidermal growth factor (EGF). The specific beta3 catecholamine agonist CI 316,243 inhibited the effects of dexamethasone on leptin release and leptin mRNA accumulation, as did EGF, without affecting 18S RNA content. Oxytocin inhibited the increase in leptin release due to dexamethasone without affecting leptin mRNA levels. These data indicate that although dexamethasone and insulin are positive regulators of leptin release, only dexamethasone specifically prevented the loss of leptin mRNA in cultured rat adipocytes. In contrast, insulin, but not dexamethasone, prevented the marked loss in 18S RNA observed over a 24-hour incubation of rat adipocytes.
authors.affiliation: Department of Biochemistry, College of Medicine, University of Tennessee, Memphis 38163, USA.
authors.forename: J N
authors.initials: JN
authors.lastname: Fain
authors.forename: S W
authors.initials: SW
authors.lastname: Bahouth
mesh_terms: D017667:Adipocytes / Q000187:drug effects / Q000378:metabolism*; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000818:Animals; D005576:Colforsin / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D004149:Dioxoles / Q000494:pharmacology; D004815:Epidermal Growth Factor / Q000494:pharmacology; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000235:genetics; D007037:Hypothyroidism / Q000378:metabolism*; D007328:Insulin / Q000494:pharmacology; D020738:Leptin; D008297:Male; D010121:Oxytocin / Q000494:pharmacology; D011506:Proteins / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics; D012337:RNA, Ribosomal, 18S / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
chemical_list: D000318:Adrenergic beta-Agonists; D004149:Dioxoles; D007328:Insulin; D020738:Leptin; D011506:Proteins; D012333:RNA, Messenger; D012337:RNA, Ribosomal, 18S; C076126:disodium (R,R)-5-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)-amino)propyl)-1,3-benzodioxole-2,3-dicarboxylate; D005576:Colforsin; D010121:Oxytocin; D004815:Epidermal Growth Factor; D003907:Dexamethasone; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; D013755:Tetradecanoylphorbol Acetate